RAC1 and inflammatory bowel disease: By contrast, the anti-inflammatory effect of sub-cytotoxic doses of 6-TG for treating inflammatory bowel disease (IBD) is thought to be primarily due to inhibition of the small GTPase Rac1 [37,38].